Colelitiasis y colecistectomía en pacientes con insuficiencia renal crónica

Martínez-Mier, Gustavo; Quintero-Tlamapatl, J.; Méndez-López, Marco T; Ávila-Pardo, Sandro F; Troche, José María Remes

doi:10.1016/j.rgmx.2012.11.002

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that the rate in patients undergoing hemodialysis was 34.6%, which was significantly higher than the 12.9% rate in their control group 21 . Martínez‐Mier et al reported gallstone prevalence as 22% in patients undergoing hemodialysis and 30% in patients undergoing peritoneal dialysis 22 . Otsuka et al investigated the effects of cinacalcet treatment on gallstones in patients undergoing hemodialysis and reported the prevalence of gallstones as 47.8% in the cinacalcet treatment group and 15.8% in the control group.…”

Section: Discussionmentioning

confidence: 90%

“…21 Martínez-Mier et al reported gallstone prevalence as 22% in patients undergoing hemodialysis and 30% in patients undergoing peritoneal dialysis. 22 Otsuka et al investigated the effects of cinacalcet treatment on gallstones in patients undergoing hemodialysis and reported the prevalence of gallstones as 47.8% in the cinacalcet treatment group and 15.8% in the control group. They reported that the highest statistically significant prevalence of gallstones was detected in the group receiving cinacalcet treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of hepatosteatosis and gallstone disease in patients with chronic kidney disease

Karahan,

Şahin

2024

Hemodialysis International

View full text Add to dashboard Cite

IntroductionThe prevalence rates of hepatosteatosis and gallstones are increasing owing to the multifactorial causes of chronic kidney disease, and the prevalence may change with the availability of different forms of renal replacement therapy. We aimed to determine the incidence or prevalence rates of hepatosteatosis, cholelithiasis, and acute cholecystitis in patients with chronic kidney disease and compare them between renal replacement therapy modalities.MethodsA total of 270 patients (90 with chronic kidney disease stages III–V, 90 undergoing peritoneal dialysis, and 90 undergoing hemodialysis) were included and categorized into the pre‐dialysis, hemodialysis, and peritoneal dialysis groups. The patients were questioned about previous gallbladder surgeries and chronic diseases. The results of abdominal ultrasonography, tomography, and magnetic resonance imaging were retrospectively evaluated with respect to the findings on the hepatobiliary system. Hepatosteatosis and cholelithiasis were diagnosed by expert radiologists on the basis of abdominal ultrasonography, tomography, and magnetic resonance imaging findings. The prevalence rates of hepatosteatosis, cholelithiasis, and other liver findings were compared between the groups.FindingsHepatosteatosis and cholelithiasis were detected in 16.7% and 21.5% of the 270 cases, respectively. Hepatosteatosis was present in 17.8%, 25.6%, and 6.7% of patients in the pre‐dialysis, hemodialysis, and peritoneal dialysis groups, respectively. The prevalence of hepatosteatosis was significantly higher in patients undergoing hemodialysis than in patients undergoing peritoneal dialysis (p = 0.002). However, no statistically significant difference was found between the peritoneal dialysis and pre‐dialysis groups or between the hemodialysis and pre‐dialysis groups (p >0.05). The prevalence rates of cholelithiasis were 15.6%, 28.9%, and 20.0%, in the pre‐dialysis, hemodialysis, and peritoneal dialysis groups, respectively, and there were no statistically significant differences among the groups. The incidence of acute cholecystitis was significantly higher in the hemodialysis group than in the pre‐dialysis group (p = 0.006).DiscussionOur study showed that the hepatobiliary system is frequently affected in chronic kidney disease and that the findings may differ depending on the renal replacement therapy modality.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%